Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

December 31, 1997

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
AnemiaLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

epoetin alfa

PROCEDURE

quality-of-life assessment

Trial Locations (18)

10021

Memorial Sloan-Kettering Cancer Center, New York

20037

George Washington University Medical Center, Washington D.C.

21201

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

27710

Duke Comprehensive Cancer Center, Durham

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

60612

Rush Cancer Institute, Chicago

92262

Comprehensive Cancer Centers of the Desert, Palm Springs

94304

Division of Oncology, Palo Alto

94704

Alta Bates Comprehensive Cancer Center, Berkeley

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

60637-1470

University of Chicago Cancer Research Center, Chicago

02215

Beth Israel Deaconess Medical Center, Boston

14263-0001

Roswell Park Cancer Institute, Buffalo

17033-0850

Milton S. Hershey Medical Center, Hershey

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00003341 - Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | Biotech Hunter | Biotech Hunter